Key Capital announces positive liver cancer immunotherapy results: 7 insights – Becker’s ASC Review
|
Key Capital announces positive liver cancer immunotherapy results: 7 insights
Becker’s ASC Review 2. Key Capital proved it was safe and highly effective in treating 75 advanced liver cancer patients through a phase II study. 3. More than 90 percent of patients were alive after a 12 month follow-up. A competitor product touts a 10 percent survival … |
